AbbVie Inc. (ABBV) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript

SA Transcripts158.38K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call AbbVie Inc. (ABBV) Piper Sandler Virtual Novel Targets in Immunology Symposium February 13, 2026 10:00 AM EST Company Participants Roopal Thakkar - Executive VP of Research and Development & Chief Scientific OfficerKori Wallace Conference Call Participants David Amsellem - Piper Sandler & Co., Research Division Presentation David AmsellemPiper Sandler & Co., Research Division Good morning, everyone, and well, happy Friday, the 13th. And on a serious note, thanks for joining us for day 2 of our Piper's Virtual Immunology Symposium. So we're delighted to have AbbVie with us. We have Chief Scientific Officer, Roopal Thakkar. We also have Kori Wallace, who is Vice President, Immunology Development -- sorry, R&D, Immunology. So I want to make sure I didn't mangle that too badly. But thanks so much for doing this. And I know there's a ton to talk about. And so I think a good place to start, quite honestly, would be on data readouts as we -- as the year progresses. Question-and-Answer Session David AmsellemPiper Sandler & Co., Research Division So the 2 drugs that come to mind, Roopal and Kori are lutekizumab and RINVOQ in HS. So with that in mind, with Ludy in HS, how do you see the potential for clinical differentiation given what is a mechanistically distinct approach here, IL-1 alpha, IL-1 beta, particularly relative to HUMIRA and COSENTYX. So particularly interested in how you're framing the potential for differentiation in what is a pretty significant unmet medical need in HS. Roopal ThakkarExecutive VP of Research and Development & Chief Scientific Officer Well, thank you, David. Thanks for having us, and thank you to your audience for listening in here today. I think you -- what you mentioned about differentiation is very important. And we've learned some things over the years with HUMIRA and HS. Remember, that